Uzor C. Ogbu

525 total citations
27 papers, 346 citations indexed

About

Uzor C. Ogbu is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Uzor C. Ogbu has authored 27 papers receiving a total of 346 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 6 papers in Genetics. Recurrent topics in Uzor C. Ogbu's work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Uzor C. Ogbu is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Uzor C. Ogbu collaborates with scholars based in United States, Netherlands and Italy. Uzor C. Ogbu's co-authors include Onyebuchi A. Arah, Gert P. Westert, Karien Stronks, Shahram Lotfipour, Bharath Chakravarthy, C. Maarten A. Schipper, Chantal W.P.M. Hukkelhoven, R Gijsen, Agnes de Bruin and Craig L. Anderson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Uzor C. Ogbu

24 papers receiving 335 citations

Peers

Countries citing papers authored by Uzor C. Ogbu

Since Specialization

Citations

This map shows the geographic impact of Uzor C. Ogbu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uzor C. Ogbu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uzor C. Ogbu more than expected).

Fields of papers citing papers by Uzor C. Ogbu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uzor C. Ogbu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uzor C. Ogbu. The network helps show where Uzor C. Ogbu may publish in the future.

Co-authorship network of co-authors of Uzor C. Ogbu

This figure shows the co-authorship network connecting the top 25 collaborators of Uzor C. Ogbu. A scholar is included among the top collaborators of Uzor C. Ogbu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uzor C. Ogbu. Uzor C. Ogbu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy 2025 ·Future Oncology ·Helmneh M. Sineshaw, (unknown), Enrico De Nigris, Jennifer Prescott, Uzor C. Ogbu, (unknown), Laura L. Fernandes, (unknown)	0
2	Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study 2024 ·Blood ·Ingrid Glimelius, Won Seog Kim, Ewa Paszkiewicz‐Kozik, (unknown), Reid W. Merryman, Cláudia Moreira, Sanfang Tu, Yixin Ren, (unknown), Uzor C. Ogbu, Pier Luigi Zinzani	1
3	A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy 2024 ·Blood ·Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, (unknown), Jean‐Jacques Kiladjian, (unknown), Harinder Gill, Kristen Pettit, David M. Ross, (unknown), (unknown), Ahmet Muzaffer Demir, (unknown), (unknown), (unknown), (unknown), (unknown), Uzor C. Ogbu, Keita Kirito	0
4	Real-World Characteristics, Treatment Patterns, and Outcomes of Patients with Mantle Cell Lymphoma By LOT 2024 ·Blood ·Helmneh M. Sineshaw, (unknown), Enrico De Nigris, Jennifer Prescott, Uzor C. Ogbu, (unknown), Laura L. Fernandes, (unknown)	0
5	Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study 2024 ·Blood ·Ewa Paszkiewicz‐Kozik, Cláudia Moreira, Mehmet Turgut, (unknown), Ingrid Glimelius, Seung‐Tae Lee, Yazeed Sawalha, Yixin Ren, (unknown), Uzor C. Ogbu, Diego Villa	1
6	A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006 2023 ·Hematological Oncology ·Pier Luigi Zinzani, Jiřı́ Mayer, Ohad Benjamini, (unknown), Ingrid Glimelius, Don A. Stevens, Arvind Chaudhry, Ahmet Muzaffer Demir, (unknown), W. S. Kim, Fei Li, (unknown), Ana Marín‐Niebla, Muhıt Özcan, Ewa Paszkiewicz‐Kozik, Armando Santoro, Yi Ren, Uzor C. Ogbu, Patricia Marinello, Wojciech Jurczak	2
7	Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study 2023 ·Hematological Oncology ·(unknown), Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, William G. Wierda, Moon Young Choi, Avyakta Kallam, (unknown), Uzor C. Ogbu, Patricia Marinello, Stephen E. Spurgeon	3
8	waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies. 2023 ·Journal of Clinical Oncology ·Pier Luigi Zinzani, Jiří Mayer, Ohad Benjamini, (unknown), Ingrid Glimelius, Don A. Stevens, Arvind Chaudhry, Ahmet Muzaffer Demir, Ramón García‐Sánz, Won Seog Kim, Fei Li, (unknown), Ana Marín‐Niebla, Muhıt Özcan, Ewa Paszkiewicz‐Kozik, Armando Santoro, Yixin Ren, Uzor C. Ogbu, Patricia Marinello, Wojciech Jurczak	2
9	Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study 2022 ·Blood ·Ranjana H. Advani, Abraham Avigdor, Anna Sureda, David Lavie, Stefan Hohaus, Jan Maciej Zaucha, (unknown), Vittorio Ruggero Zilioli, (unknown), Muhıt Özcan, (unknown), Uzor C. Ogbu, Akash Nahar, Jane N. Winter	3
10	Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma 2020 ·Pharmaceutical Research ·Dan Lü, Tong Lu, (unknown), Leonid Gibiansky, Priya Agarwal, Colby S. Shemesh, Randall Dere, Uzor C. Ogbu, Jamie Hirata, Pascal Chanu, Sandhya Girish, Jin Y. Jin, Chunze Li, Dale Miles	13
11	Polysubstance Abuse: Alcohol, Opioids and Benzodiazepines Require Coordinated Engagement by Society, Patients, and Physicians 2015 ·Western Journal of Emergency Medicine ·Uzor C. Ogbu, Shahram Lotfipour, Bharath Chakravarthy	22
12	Patient Motivators for Emergency Department Utilization: A Pilot Cross-Sectional Survey of Uninsured Admitted Patients at a University Teaching Hospital 2015 ·Journal of Emergency Medicine ·(unknown), Uzor C. Ogbu, Alpesh Amin, Bharath Chakravarthy, Craig L. Anderson, Shahram Lotfipour	13
13	A retrospective analysis of ethnic and gender differences in alcohol consumption among emergency department patients: a cross-sectional study 2015 ·BMC Emergency Medicine ·Shahram Lotfipour, (unknown), Uzor C. Ogbu, Christopher Eric McCoy, Cristobal Barrios, Craig L. Anderson, Wirachin Hoonpongsimanont, (unknown), Bharath Chakravarthy	8
14	Determinants of Pediatric Psychiatry Length of Stay in 2 Urban Emergency Departments 2015 ·Pediatric Emergency Care ·Bharath Chakravarthy, Allen Y. Yang, Uzor C. Ogbu, (unknown), (unknown), (unknown), Craig A. Anderson, (unknown), Tim A. Bruckner, (unknown), (unknown), Shahram Lotfipour	14
15	Regulating quality and safety of health and social care 2014 ·Research Portal (King's College London) ·(unknown), Saba Hinrichs, Uzor C. Ogbu, Eric C. Schneider, Dionne Kringos, Niek Klazinga, Judith Healy, Lauri Vuorenkoski, Reinhard Busse, (unknown), Emma Pitchforth, Ellen Nolte	2
16	Using Quality Measures for Quality Improvement: The Perspective of Hospital Staff 2014 ·PLoS ONE ·(unknown), Hamid Ravaghi, Dionne Kringos, Uzor C. Ogbu, Claudia Fischer, (unknown), Niek Klazinga	15
17	Regulating quality and safety of health and social care: International experiences 2014 ·RAND Corporation eBooks ·(unknown), Saba Hinrichs, Uzor C. Ogbu, Eric C. Schneider, Dionne Kringos, Niek Klazinga, Judith Healy, Lauri Vuorenkoski, Reinhard Busse, (unknown), Emma Pitchforth, Ellen Nolte	14
18	Effects of hospital delivery during off-hours on perinatal outcome in several subgroups: a retrospective cohort study 2012 ·BMC Pregnancy and Childbirth ·R Gijsen, Chantal W.P.M. Hukkelhoven, C. Maarten A. Schipper, Uzor C. Ogbu, (unknown), Gert P. Westert	46
19	Hospital Stroke Volume and Case-Fatality Revisited 2010 ·Medical Care ·Uzor C. Ogbu, (unknown), Onyebuchi A. Arah, Agnes de Bruin, Karien Stronks, Gert P. Westert	24
20	A multifaceted look at time of admission and its impact on case-fatality among a cohort of ischaemic stroke patients 2010 ·Journal of Neurology Neurosurgery & Psychiatry ·Uzor C. Ogbu, Gert P. Westert, (unknown), Karien Stronks, Onyebuchi A. Arah	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact